EGFR and cancer: Wilken et al. demonstrated that two EGFR-directed antibodies, cetuximab and panitumumab, recognize and bind sEGFR even at very low doses, suggesting that interactions between sEGFR and antibodies may be relevant in calculating the effective dose of these drugs in cancer patients43.